Cargando…
A Combinatorial Cell and Drug Delivery Strategy for Huntington’s Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells
For Huntington’s disease (HD) cell-based therapy, the transplanted cells are required to be committed to a neuronal cell lineage, survive and maintain this phenotype to ensure their safe transplantation in the brain. We first investigated the role of RE-1 silencing transcription factor (REST) inhibi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835496/ https://www.ncbi.nlm.nih.gov/pubmed/31614758 http://dx.doi.org/10.3390/pharmaceutics11100526 |
_version_ | 1783466685989126144 |
---|---|
author | André, Emilie M. Delcroix, Gaëtan J. Kandalam, Saikrishna Sindji, Laurence Montero-Menei, Claudia N. |
author_facet | André, Emilie M. Delcroix, Gaëtan J. Kandalam, Saikrishna Sindji, Laurence Montero-Menei, Claudia N. |
author_sort | André, Emilie M. |
collection | PubMed |
description | For Huntington’s disease (HD) cell-based therapy, the transplanted cells are required to be committed to a neuronal cell lineage, survive and maintain this phenotype to ensure their safe transplantation in the brain. We first investigated the role of RE-1 silencing transcription factor (REST) inhibition using siRNA in the GABAergic differentiation of marrow-isolated adult multilineage inducible (MIAMI) cells, a subpopulation of MSCs. We further combined these cells to laminin-coated poly(lactic-co-glycolic acid) PLGA pharmacologically active microcarriers (PAMs) delivering BDNF in a controlled fashion to stimulate the survival and maintain the differentiation of the cells. The PAMs/cells complexes were then transplanted in an ex vivo model of HD. Using Sonic Hedgehog (SHH) and siREST, we obtained GABAergic progenitors/neuronal-like cells, which were able to secrete HGF, SDF1 VEGFa and BDNF, of importance for HD. GABA-like progenitors adhered to PAMs increased their mRNA expression of NGF/VEGFa as well as their secretion of PIGF-1, which can enhance reparative angiogenesis. In our ex vivo model of HD, they were successfully transplanted while attached to PAMs and were able to survive and maintain this GABAergic neuronal phenotype. Together, our results may pave the way for future research that could improve the success of cell-based therapy for HDs. |
format | Online Article Text |
id | pubmed-6835496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68354962019-11-25 A Combinatorial Cell and Drug Delivery Strategy for Huntington’s Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells André, Emilie M. Delcroix, Gaëtan J. Kandalam, Saikrishna Sindji, Laurence Montero-Menei, Claudia N. Pharmaceutics Article For Huntington’s disease (HD) cell-based therapy, the transplanted cells are required to be committed to a neuronal cell lineage, survive and maintain this phenotype to ensure their safe transplantation in the brain. We first investigated the role of RE-1 silencing transcription factor (REST) inhibition using siRNA in the GABAergic differentiation of marrow-isolated adult multilineage inducible (MIAMI) cells, a subpopulation of MSCs. We further combined these cells to laminin-coated poly(lactic-co-glycolic acid) PLGA pharmacologically active microcarriers (PAMs) delivering BDNF in a controlled fashion to stimulate the survival and maintain the differentiation of the cells. The PAMs/cells complexes were then transplanted in an ex vivo model of HD. Using Sonic Hedgehog (SHH) and siREST, we obtained GABAergic progenitors/neuronal-like cells, which were able to secrete HGF, SDF1 VEGFa and BDNF, of importance for HD. GABA-like progenitors adhered to PAMs increased their mRNA expression of NGF/VEGFa as well as their secretion of PIGF-1, which can enhance reparative angiogenesis. In our ex vivo model of HD, they were successfully transplanted while attached to PAMs and were able to survive and maintain this GABAergic neuronal phenotype. Together, our results may pave the way for future research that could improve the success of cell-based therapy for HDs. MDPI 2019-10-12 /pmc/articles/PMC6835496/ /pubmed/31614758 http://dx.doi.org/10.3390/pharmaceutics11100526 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article André, Emilie M. Delcroix, Gaëtan J. Kandalam, Saikrishna Sindji, Laurence Montero-Menei, Claudia N. A Combinatorial Cell and Drug Delivery Strategy for Huntington’s Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells |
title | A Combinatorial Cell and Drug Delivery Strategy for Huntington’s Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells |
title_full | A Combinatorial Cell and Drug Delivery Strategy for Huntington’s Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells |
title_fullStr | A Combinatorial Cell and Drug Delivery Strategy for Huntington’s Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells |
title_full_unstemmed | A Combinatorial Cell and Drug Delivery Strategy for Huntington’s Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells |
title_short | A Combinatorial Cell and Drug Delivery Strategy for Huntington’s Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells |
title_sort | combinatorial cell and drug delivery strategy for huntington’s disease using pharmacologically active microcarriers and rnai neuronally-committed mesenchymal stromal cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835496/ https://www.ncbi.nlm.nih.gov/pubmed/31614758 http://dx.doi.org/10.3390/pharmaceutics11100526 |
work_keys_str_mv | AT andreemiliem acombinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells AT delcroixgaetanj acombinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells AT kandalamsaikrishna acombinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells AT sindjilaurence acombinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells AT monteromeneiclaudian acombinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells AT andreemiliem combinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells AT delcroixgaetanj combinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells AT kandalamsaikrishna combinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells AT sindjilaurence combinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells AT monteromeneiclaudian combinatorialcellanddrugdeliverystrategyforhuntingtonsdiseaseusingpharmacologicallyactivemicrocarriersandrnaineuronallycommittedmesenchymalstromalcells |